Resonantly Coupled High-Efficiency Sensors for Assessment of Ventricular Chamber Size for Autonomous Control of Left Ventricular Assist Device
- PMID: 36346948
- DOI: 10.1097/MAT.0000000000001846
Resonantly Coupled High-Efficiency Sensors for Assessment of Ventricular Chamber Size for Autonomous Control of Left Ventricular Assist Device
Abstract
Current left ventricular assist devices (LVADs) are set to a fixed rpm and are unable to adjust to physiological demands irrespective of preload or afterload. Autonomous control of LVADs has the potential to reduce septal shift, preserve right ventricle function, and meet physiological demands. A highly innovative resonantly coupled regimen is presented which can achieve this goal. We introduce sensors based on a highly sensitive relationship between transmission coefficient and spatial separation in a resonantly coupled regimen. This relationship represents a polynomial regression. A regimen of an apical sensor and multiple outflow sensors is investigated. A range of separations varying from 50-200 mm was systematically investigated. These ranges consider anatomical & physiological variation(s) in cardiac chamber size. Validation was obtained in porcine heart preparation. The polynomial regression model predicted distance between the sensors with a mean absolute percentage error of 0.77%, 1.07%, and 5.75% for the three putative positions of the outflow sensors and apical sensor when compared with experimental results. A high degree of accuracy (95%) between the predicted and observed distance was obtained. Continuous measurements were done over 90 days to examine drift, with no statistically detectable change in measurements over million sampling cycles. We have demonstrated a reliable sensor methodology without drift for assessing ventricular chamber size in an LVAD setup. This has the potential to allow autonomous control of LVAD based on ventricular chamber size to address some of the adverse events.
Copyright © ASAIO 2022.
Conflict of interest statement
Disclosure: There are no conflicts of interest.
Comment in
-
Toward a Self-Actuating Continuous Flow Ventricular Assist Device: The Pudding Is in the Proof.ASAIO J. 2023 Jan 1;69(1):59-60. doi: 10.1097/MAT.0000000000001881. Epub 2022 Dec 28. ASAIO J. 2023. PMID: 36583771 No abstract available.
References
-
- Goldstein DJ, Naka Y, Horstmanshof D, et al.: Association of clinical outcomes with left ventricular assist device use by bridge to transplant or destination therapy intent the multicenter study of maglev technology in patients undergoing mechanical circulatory support therapy with heartmate 3 (momentum 3) randomized clinical trial. JAMA Cardiol. 5: 411–419, 2020.
-
- Angud M: Left ventricular assist device driveline infections: the Achilles’ heel of destination therapy. AACN Adv Crit Care. 26: 300–305, 2015.
-
- Milano CA, Rogers JG, Tatooles AJ, et al.: HVAD: the ENDURANCE supplemental trial. JACC: Heart Fail. 6: 792–802, 2018.
-
- Mori M, McCloskey G, Geirsson A, et al.: Improving outcomes in INTERMACS category 1 patients with pre-LVAD, awake venous-arterial extracorporeal membrane oxygenation support. ASAIO. 65: 819–826, 2019.
-
- Slaughter MS, Pagani FD, McGee EC, et al.: HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial. J Heart Lung Transplant. 32: 675–683, 2013.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
